AGIM has a permanent policy of valorization in a long-term vision of translational medicine from basic research, drug discovery, technological research in the field of engineering sciences and applied research dedicated to technologies - services for ageing and physiological applications.

Daniel CHRISTIAEN  (CNRS) is in charge of the AGIM’S valorization policy.